Investigation of molecular markers of lung cancer to predict drug response
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
We sought to investigate the relationship between EGFR mutation and increases in EGFR or HER2 copy number and response to treatment with a small molecular inhibitor of EGFR, gefitinib/Iressa. Through DNA sequence and FISH analysis of archival biopsy samples from 37 patients, we found none of these features to be diagnostic of response. Identification of additional predictive biomarkers beyond EGFR status may be necessary to accurately predict outcome to treatment with targeted therapies.
Full Citation
Pugh TJ, Bebb G, Barclay L, Sutcliffe M, Fee J, Salski C, O'Connor R, Ho C, Murray N, Melosky B, English J, Vielkind J, Horsman D, Laskin JJ & Marra MA. BMC Cancer 2007. 7(1):128.
Further details of this publication can be found online at:
http://www.biomedcentral.com/1471-2407/7/128
For more information please contact info@bcgsc.ca
Full Citation
Pugh TJ, Bebb G, Barclay L, Sutcliffe M, Fee J, Salski C, O'Connor R, Ho C, Murray N, Melosky B, English J, Vielkind J, Horsman D, Laskin JJ & Marra MA. BMC Cancer 2007. 7(1):128.
Further details of this publication can be found online at:
http://www.biomedcentral.com/1471-2407/7/128
For more information please contact info@bcgsc.ca
Page last modified
Jul 28, 2008